

# Aaron S Kesselheim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6638625/publications.pdf>

Version: 2024-02-01

568  
papers

15,396  
citations

22153

59  
h-index

38395

95  
g-index

581  
all docs

581  
docs citations

581  
times ranked

15603  
citing authors

#	ARTICLE	IF	CITATIONS
1	US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 542-544.	4.7	14
2	Payer-Specific Negotiated Prices for Prescription Drugs at Top-Performing US Hospitals. <i>JAMA Internal Medicine</i> , 2022, 182, 83.	5.1	7
3	Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling. <i>Journal of Clinical Oncology</i> , 2022, 40, 1102-1110.	1.6	3
4	Reporting bias in clinical trials: Progress toward transparency and next steps. <i>PLoS Medicine</i> , 2022, 19, e1003894.	8.4	9
5	Differences in Diabetic Prescription Drug Utilization and Costs Among Patients With Diabetes Enrolled in Colorado Marketplace and Medicaid Plans, 2014-2015. <i>JAMA Network Open</i> , 2022, 5, e2140371.	5.9	2
6	Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020. <i>JAMA Internal Medicine</i> , 2022, 182, 342.	5.1	4
7	Extending Drug Monopolies by Patenting Safe Drug Use. <i>JAMA Internal Medicine</i> , 2022, , .	5.1	2
8	Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases. <i>Journal of Law and the Biosciences</i> , 2022, 9, Isac001.	1.6	5
9	The characteristics of patents impacting availability of biosimilars. <i>Nature Biotechnology</i> , 2022, 40, 22-25.	17.5	9
10	Performance-Linked Reimbursement and the Uncertainty of Novel Drugs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, e008642.	2.2	1
11	Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use. <i>JAMA Network Open</i> , 2022, 5, e2144386.	5.9	7
12	Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer. <i>JAMA Oncology</i> , 2022, 8, 537.	7.1	11
13	Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care. <i>Journal of General Internal Medicine</i> , 2022, , 1.	2.6	1
14	A New Way to Contain Unaffordable Medication Costs – Exercising the Government's Existing Rights. <i>New England Journal of Medicine</i> , 2022, 386, 1104-1106.	27.0	5
15	New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence. <i>Drug Safety</i> , 2022, 45, 305-318.	3.2	7
16	Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes. <i>Nature Biotechnology</i> , 2022, 40, 167-169.	17.5	1
17	Aducanumab and Accelerated Approval: Where Do We Go From Here?. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 726-727.	4.7	2
18	Anticipated efficiencies, real costs: Medicaid managed care organizations and the pharmacy benefit. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, 28, 354-361.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Strategies to Manage Drugs and Devices Approved Based on Limited Evidence: Results of a Modified Delphi Panel. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1307-1314.	4.7	2
20	Updating the Bayh-Dole Act. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 923.	7.4	4
21	Switching to Over-the-Counter Availability of Rescue Inhalers for Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1021.	7.4	10
22	QALYs In Health Resource Usage Decisions: The Authors Reply. <i>Health Affairs</i> , 2022, 41, 610-610.	5.2	0
23	Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. <i>Lancet Oncology</i> , The, 2022, 23, 514-520.	10.7	22
24	Making the Case for Accelerated Withdrawal of Aducanumab. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1003-1007.	2.6	19
25	Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019. <i>JAMA Network Open</i> , 2022, 5, e226479.	5.9	8
26	Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability. <i>JAMA - Journal of the American Medical Association</i> , 2022, , .	7.4	4
27	Direct-to-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures?. <i>Annals of Internal Medicine</i> , 2022, 175, 890-891.	3.9	3
28	Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration. <i>JAMA Network Open</i> , 2022, 5, e227958.	5.9	8
29	Medicaid Expenditures and Estimated Rebates on Line Extension Drugs, 2010â€“2018. <i>Journal of General Internal Medicine</i> , 2022, , .	2.6	5
30	State Laws and Generic Substitution in the Year After New Generic Competition. <i>Value in Health</i> , 2022, , .	0.3	1
31	Coverage of New Drugs in Medicare Part D. <i>Milbank Quarterly</i> , 2022, 100, 562-588.	4.4	3
32	Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved Drugs. <i>Health Affairs</i> , 2022, 41, 713-721.	5.2	7
33	Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020. <i>JAMA Network Open</i> , 2022, 5, e2212454.	5.9	11
34	Institutionalizing Misinformation â€” The Dietary Supplement Listing Act of 2022. <i>New England Journal of Medicine</i> , 2022, 387, 3-5.	27.0	4
35	Improving the quality of US drug patents through international awareness. <i>BMJ</i> , The, 2022, 377, e068172.	6.0	3
36	Postâ€“Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004â€“2014. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 846-852.	4.7	2

#	ARTICLE	IF	CITATIONS
37	Trends in Prescription Drug Launch Prices, 2008-2021. JAMA - Journal of the American Medical Association, 2022, 327, 2145.	7.4	45
38	Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncology Practice, 2022, 18, e1522-e1532.	2.9	16
39	Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company. Annals of Internal Medicine, 2022, 175, 1053-1055.	3.9	10
40	Over-the-Counter Availability of Rescue Inhalers for Asthma—Reply. JAMA - Journal of the American Medical Association, 2022, 328, 216.	7.4	1
41	Payments for research participation: Don't tax the Guinea pig. Clinical Trials, 2022, 19, 579-583.	1.6	1
42	Federal Spending on Off-Patent Drugs That Lack Generic Competition. Journal of General Internal Medicine, 2021, 36, 821-823.	2.6	4
43	Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012–2018. Clinical Pharmacology and Therapeutics, 2021, 109, 367-371.	4.7	26
44	Reply to Boucher et al. Clinical Infectious Diseases, 2021, 72, e422-e423.	5.8	0
45	Public funding for transformative drugs: the case of sofosbuvir. Drug Discovery Today, 2021, 26, 273-281.	6.4	10
46	An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19. Health Affairs, 2021, 40, 25-32.	5.2	27
47	Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. Drug Safety, 2021, 44, 327-335.	3.2	4
48	Factors Affecting Buprenorphine Utilization and Spending in Medicaid, 2002-2018. Value in Health, 2021, 24, 182-187.	0.3	6
49	The Wrong Cure: Financial Incentives for Unimpressive New Antibiotics. Journal of Infectious Diseases, 2021, 223, 1506-1509.	4.0	3
50	Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions. JAMA Internal Medicine, 2021, 181, 16.	5.1	22
51	INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development — Historical Scope, Opportunities, and Challenges. Journal of Law, Medicine and Ethics, 2021, 49, 6-9.	0.9	4
52	A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer. EClinicalMedicine, 2021, 32, 100730.	7.1	9
53	Buprenorphine for opioid use disorder: The role of public funding in its development. Drug and Alcohol Dependence, 2021, 219, 108491.	3.2	6
54	ASHP Foundation Pharmacy Forecast 2021: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2021, 78, 472-497.	1.0	12

#	ARTICLE	IF	CITATIONS
55	The Future of Drug-Pricing Transparency. <i>New England Journal of Medicine</i> , 2021, 384, 489-491.	27.0	11
56	Associations Between Copays, Coverage Limits for Opioid Use Disorder Medications, and Prescribing in Medicaid, 2018. <i>Medical Care</i> , 2021, 59, 266-272.	2.4	0
57	Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after <i>United States v. Caronia</i> : An Analysis of Litigated Cases. <i>Journal of Health Politics, Policy and Law</i> , 2021, 46, 487-504.	1.9	3
58	Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation. <i>Milbank Quarterly</i> , 2021, 99, 240-272.	4.4	14
59	Trends in Medicare Part D Inhaler Spending: 2012–2018. <i>Annals of the American Thoracic Society</i> , 2021, 18, 548-550.	3.2	8
60	Frequency of First Generic Drug Approvals With “Skinny Labels” in the United States. <i>JAMA Internal Medicine</i> , 2021, 181, 995-997.	5.1	8
61	Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study. <i>American Heart Journal</i> , 2021, 233, 109-121.	2.7	23
62	FDA approval standards for anticancer agents – lessons from two recent approvals in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 397-398.	27.6	4
63	Paying for Prescription Drugs in the New Administration. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 819.	7.4	9
64	Identifying potential prescription drug product hopping. <i>Nature Biotechnology</i> , 2021, 39, 414-417.	17.5	2
65	Public funding and the importance of reasonable pricing for buprenorphine. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108643.	3.2	0
66	International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects. <i>Value in Health</i> , 2021, 24, 473-476.	0.3	7
67	A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs. <i>Drug Safety</i> , 2021, 44, 743-751.	3.2	7
68	Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020. <i>JAMA Network Open</i> , 2021, 4, e218530.	5.9	2
69	Substitution of Generic Drugs and Biosimilars – Reply. <i>JAMA Internal Medicine</i> , 2021, 181, 568.	5.1	0
70	Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. <i>JAMA Internal Medicine</i> , 2021, 181, 490.	5.1	32
71	Frequency Of Generic Drug Price Spikes And Impact On Medicaid Spending. <i>Health Affairs</i> , 2021, 40, 779-785.	5.2	4
72	Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs. <i>JAMA Network Open</i> , 2021, 4, e218816.	5.9	15

#	ARTICLE	IF	CITATIONS
73	Evaluation of Aducanumab for Alzheimer Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1717.	7.4	152
74	Integrating New Effectiveness Data Into US Food and Drug Administrationâ€“Approved Drug Labeling. JAMA Internal Medicine, 2021, 181, 897-898.	5.1	5
75	The timing of 30â€“month stay expirations and generic entry: A cohort study of first generics, 2013â€“2020. Clinical and Translational Science, 2021, 14, 1917-1923.	3.1	5
76	Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear. Health Affairs, 2021, 40, 772-778.	5.2	5
77	Association of Californiaâ€™s Prescription Drug Coupon Ban With Generic Drug Use. JAMA - Journal of the American Medical Association, 2021, 325, 2399.	7.4	2
78	Estimating Rebates and Other Discounts Received by Medicare Part D. JAMA Health Forum, 2021, 2, e210626.	2.2	18
79	Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017. Value in Health, 2021, 24, 804-811.	0.3	8
80	Continual learning in medical devices: FDA's action plan and beyond. The Lancet Digital Health, 2021, 3, e337-e338.	12.3	43
81	Fulfilling the Mandate of the US Food and Drug Administrationâ€™s Accelerated Approval Pathway. JAMA Internal Medicine, 2021, 181, 1275.	5.1	34
82	Public-sector Contributions to Novel Biologic Drugs. JAMA Internal Medicine, 2021, 181, 1522.	5.1	6
83	Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development Speed. Clinical Pharmacology and Therapeutics, 2021, 110, 1018-1024.	4.7	11
84	Cost to Medicare of Delayed Adalimumab Biosimilar Availability. Clinical Pharmacology and Therapeutics, 2021, 110, 1050-1056.	4.7	11
85	FDA Regulation and Approval of Medical Devices: 1976-2020. JAMA - Journal of the American Medical Association, 2021, 326, 420.	7.4	53
86	Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation. Health Affairs, 2021, 40, 1198-1205.	5.2	15
87	Will Ending the Medicaid Drug Rebate Cap Lower Drug Prices?. JAMA Internal Medicine, 2021, 181, 1034.	5.1	11
88	Pursuing Valueâ€“Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drugâ€“Pricing Boards. Milbank Quarterly, 2021, , .	4.4	3
89	Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative. JAMA Internal Medicine, 2021, 181, 1124.	5.1	4
90	Revisiting FDA Approval of Aducanumab. New England Journal of Medicine, 2021, 385, 769-771.	27.0	104

#	ARTICLE	IF	CITATIONS
91	Discovery and Development of Pregabalin (Lyrica). <i>Neurology</i> , 2021, 97, e1653-e1660.	1.1	1
92	Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. <i>JAMA Oncology</i> , 2021, 7, e212026.	7.1	46
93	A Court Decision on “Skinny Labeling”. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1371.	7.4	6
94	Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic. <i>Journal of General Internal Medicine</i> , 2021, 36, 3918-3921.	2.6	0
95	Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?. <i>Value in Health</i> , 2021, 24, 1328-1334.	0.3	8
96	Controversy Over Using Quality-Adjusted Life-Years In Cost-Effectiveness Analyses: A Systematic Literature Review. <i>Health Affairs</i> , 2021, 40, 1402-1410.	5.2	17
97	International reference pricing for prescription drugs: a landscape analysis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1309-1313.	0.9	3
98	Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. <i>BMJ, The</i> , 2021, 374, n1959.	6.0	40
99	Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 3.	2.4	28
100	Over-the-Counter Monograph Safety, Innovation, and Reform Act. <i>Journal of Law, Medicine and Ethics</i> , 2021, 49, 321-327.	0.9	1
101	COPD EXACERBATIONS AND PNEUMONIA HOSPITALIZATIONS IN NEW USERS OF COMBINATION MAINTENANCE INHALERS: A COMPARATIVE EFFECTIVENESS AND SAFETY STUDY. <i>Chest</i> , 2021, 160, A1795.	0.8	1
102	Medicare Spending on Drugs With Accelerated Approval, 2015-2019. <i>JAMA Health Forum</i> , 2021, 2, e213937.	2.2	8
103	Promoting Competition in Drug Pricing: A Review of Recent Congressional Legislation. <i>Journal of Law, Medicine and Ethics</i> , 2021, 49, 683-687.	0.9	0
104	Raising Medicaid Rebates For Drugs With Accelerated Approval. <i>Health Affairs</i> , 2021, 40, 1935-1942.	5.2	7
105	Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1671-1675.	5.8	11
106	US Food and Drug Administration Recommendations on the Use of Surrogate Measures as End Points in New Anti-infective Drug Approvals. <i>JAMA Internal Medicine</i> , 2020, 180, 131.	5.1	8
107	FDA and EMA Biosimilar Approvals. <i>Journal of General Internal Medicine</i> , 2020, 35, 1908-1910.	2.6	11
108	Confidentiality Orders and Public Interest in Drug and Medical Device Litigation. <i>JAMA Internal Medicine</i> , 2020, 180, 292.	5.1	4

#	ARTICLE	IF	CITATIONS
109	Novelty of Active Ingredients in High-Cost Brand-Name Drugs. <i>Journal of General Internal Medicine</i> , 2020, 35, 2219-2221.	2.6	1
110	Potential Medicare Savings on Inhaler Prescriptions Through the Use of Negotiated Prices and a Defined Formulary. <i>JAMA Internal Medicine</i> , 2020, 180, 454.	5.1	4
111	Getting the Right Evidence After Drug Approval. <i>Frontiers in Pharmacology</i> , 2020, 11, 569535.	3.5	10
112	Implementing U.S. Covid-19 Testing: Regulatory and Infrastructural Challenges. <i>Journal of Law, Medicine and Ethics</i> , 2020, 48, 608-612.	0.9	1
113	Clinical Development Times for Biosimilars in the United States. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2152-2154.	3.0	3
114	Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. <i>BMJ, The</i> , 2020, 371, m3434.	6.0	56
115	Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study. <i>Journal of the Royal Society of Medicine</i> , 2020, 113, 350-359.	2.0	2
116	Revisiting the National Institutes of Health Fair Pricing Condition: Promoting the Affordability of Drugs Developed With Government Support. <i>Annals of Internal Medicine</i> , 2020, 172, 348-350.	3.9	9
117	Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. <i>Cancer</i> , 2020, 126, 4390-4399.	4.1	19
118	US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate. <i>JAMA Internal Medicine</i> , 2020, 180, 1165.	5.1	7
119	Drug Prices, Rebates, and Discounts. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 399.	7.4	4
120	Missed Opportunities on Emergency Remdesivir Use. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 331.	7.4	15
121	Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?. <i>BMJ, The</i> , 2020, 371, m3841.	6.0	7
122	Understanding when real world data can be used to replicate a clinical trial: A cross-sectional study of medications approved in 2011. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1273-1278.	1.9	2
123	Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1284.	7.4	23
124	Up Is Down – Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval. <i>New England Journal of Medicine</i> , 2020, 383, 1706-1708.	27.0	11
125	Variations in Generic Combination Opioid Use Across State Medicaid Programs. <i>Journal of General Internal Medicine</i> , 2020, 36, 3240-3242.	2.6	0
126	A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways. <i>Nature Biotechnology</i> , 2020, 38, 1253-1256.	17.5	8



#	ARTICLE	IF	CITATIONS
127	Development of a National Public Pharmaceutical Research and Development Institute. <i>Journal of Law, Medicine and Ethics</i> , 2020, 48, 225-227.	0.9	0
128	Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies. <i>JAMA Internal Medicine</i> , 2020, 180, 1145.	5.1	21
129	Estimating The Cost Of Delayed Generic Drug Entry To Medicaid. <i>Health Affairs</i> , 2020, 39, 1011-1017.	5.2	4
130	Regulatory approval characteristics of antimicrobial versus non-antimicrobial products, 1984-2018: an evaluation of Food and Drug Administration flexibilities. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e159-e164.	9.1	3
131	Specialty Drugs - A Distinctly American Phenomenon. <i>New England Journal of Medicine</i> , 2020, 382, 2179-2181.	27.0	7
132	False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. <i>New England Journal of Medicine</i> , 2020, 383, e38.	27.0	721
133	Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs. <i>EClinicalMedicine</i> , 2020, 21, 100332.	7.1	80
134	Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018. <i>Drug Safety</i> , 2020, 43, 669-675.	3.2	14
135	Using real-world safety data in regulatory approval decisions: Sotagliflozin and the risk of diabetic ketoacidosis. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1322-1324.	1.9	3
136	Generating comparative evidence on new drugs and devices before approval. <i>Lancet</i> , The, 2020, 395, 986-997.	13.7	59
137	Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 350-357.	4.7	41
138	Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany. <i>Health Affairs</i> , 2020, 39, 1185-1193.	5.2	30
139	Comparing Onset of Biosimilar Versus Generic Competition in the United States. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1308-1314.	4.7	7
140	FDA Approval and Regulation of Pharmaceuticals, 1983-2018. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 164.	7.4	197
141	Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary. <i>JAMA Internal Medicine</i> , 2020, 180, 597.	5.1	10
142	Internet Searches for Unproven COVID-19 Therapies in the United States. <i>JAMA Internal Medicine</i> , 2020, 180, 1116.	5.1	97
143	Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. <i>Lancet Oncology</i> , The, 2020, 21, 664-670.	10.7	126
144	Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications. <i>Value in Health</i> , 2020, 23, 434-440.	0.3	6

#	ARTICLE	IF	CITATIONS
145	Insulin access and affordability in the USA: anticipating the first interchangeable insulin product. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 360-362.	11.4	4
146	Prescribing systemic steroids for acute respiratory tract infections in United States outpatient settings: A nationwide population-based cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003058.	8.4	13
147	Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1903.	7.4	9
148	Incentivizing Antibiotic Development: Why Isn't the Generating Antibiotic Incentives Now (GAIN) Act Working?. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa001.	0.9	19
149	The evidence landscape in precision medicine. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	16
150	New drug approvals in oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 140-146.	27.6	27
151	Social, cultural and economic aspects of antimicrobial resistance. <i>Bulletin of the World Health Organization</i> , 2020, 98, 823-823A.	3.3	16
152	Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 36-43.	4.9	21
153	Preferences for and Experiences With Pill Appearance Changes: National Surveys of Patients and Pharmacists. <i>American Journal of Managed Care</i> , 2020, 26, 340-347.	1.1	2
154	Generic Competition for Drugs Treating Rare Diseases. <i>Journal of Law, Medicine and Ethics</i> , 2020, 48, 789-795.	0.9	1
155	Title is missing!. , 2020, 17, e1003058.		0
156	Title is missing!. , 2020, 17, e1003058.		0
157	Title is missing!. , 2020, 17, e1003058.		0
158	Title is missing!. , 2020, 17, e1003058.		0
159	Title is missing!. , 2020, 17, e1003058.		0
160	Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. <i>Drug Safety</i> , 2019, 42, 85-93.	3.2	5
161	Patent term restoration for top-selling drugs in the United States. <i>Drug Discovery Today</i> , 2019, 24, 20-25.	6.4	18
162	The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 47-54.	2.1	10

#	ARTICLE	IF	CITATIONS
163	Why Are Biosimilars Not Living up to Their Promise in the US?. AMA Journal of Ethics, 2019, 21, E668-678.	0.7	44
164	Landscape of Cardiovascular Device Registries in the United States. Journal of the American Heart Association, 2019, 8, e012756.	3.7	3
165	Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers. JAMA Internal Medicine, 2019, 179, 1712.	5.1	8
166	Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions. Journal of General Internal Medicine, 2019, 34, 2339-2341.	2.6	27
167	Orphan Drug Designation and Exclusivity for “Same Drugs”. Journal of Law, Medicine and Ethics, 2019, 47, 347-349.	0.9	1
168	Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017. JAMA - Journal of the American Medical Association, 2019, 322, 267.	7.4	21
169	Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Safety, 2019, 42, 1287-1295.	3.2	13
170	Reforming the Orphan Drug Act for the 21st Century. New England Journal of Medicine, 2019, 381, 106-108.	27.0	31
171	Public Approval of Exception From Informed Consent in Emergency Clinical Trials. JAMA Network Open, 2019, 2, e197591.	5.9	21
172	Competition and price among brand-name drugs in the same class: A systematic review of the evidence. PLoS Medicine, 2019, 16, e1002872.	8.4	42
173	The Impact Of Price Regulation On The Availability Of New Drugs In Germany. Health Affairs, 2019, 38, 1182-1187.	5.2	19
174	Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration. JAMA Network Open, 2019, 2, e1913029.	5.9	3
175	Transparency on Prescription Drug Research Expenditures. , 2019, , 121-131.		0
176	Physician Perceptions of Step Therapy Prescribing Requirements. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1210-1224.	0.9	4
177	Prescription Opioid Epidemic and Trends in the Clinical Development of New Pain Medications. Mayo Clinic Proceedings, 2019, 94, 2437-2443.	3.0	5
178	Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e006073.	2.2	4
179	The U.S. Insulin Crisis “ Rationing a Lifesaving Medication Discovered in the 1920s. New England Journal of Medicine, 2019, 381, 1793-1795.	27.0	45
180	Public sector financial support for late stage discovery of new drugs in the United States: cohort study. BMJ: British Medical Journal, 2019, 367, l5766.	2.3	42

#	ARTICLE	IF	CITATIONS
181	Desmopressin and the risk of hyponatremia: A population-based cohort study. PLoS Medicine, 2019, 16, e1002930.	8.4	16
182	Promoting Pediatric Drug Research and Labeling “ Outcomes of Legislation. New England Journal of Medicine, 2019, 381, 875-881.	27.0	19
183	Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs. JAMA Network Open, 2019, 2, e199570.	5.9	13
184	Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey. Journal of Law, Medicine and Ethics, 2019, 47, 430-441.	0.9	9
185	Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence. Journal of Law, Medicine and Ethics, 2019, 47, 381-387.	0.9	1
186	Challenges and Opportunities for Biomarker Validation. Journal of Law, Medicine and Ethics, 2019, 47, 357-361.	0.9	9
187	Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2019, 321, 374.	7.4	31
188	Tepid Steps on Drug Pricing. JAMA Internal Medicine, 2019, 179, 439.	5.1	5
189	Physicians’s Perspectives on FDA Approval Standards and Off-label Drug Marketing. JAMA Internal Medicine, 2019, 179, 707.	5.1	17
190	Pre-market development times for biologic versus small-molecule drugs. Nature Biotechnology, 2019, 37, 708-711.	17.5	24
191	Trust and transparency in medical device regulation. BMJ: British Medical Journal, 2019, 365, l4166.	2.3	5
192	Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs. Health Policy, 2019, 123, 721-727.	3.0	4
193	Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Internal Medicine, 2019, 179, 906.	5.1	189
194	Changes in Price for Generic Drugs in the USA, 2008–2016. Journal of General Internal Medicine, 2019, 34, 1677-1679.	2.6	6
195	Approximating Future Generic Entry for New Drugs. Journal of Law, Medicine and Ethics, 2019, 47, 177-182.	0.9	3
196	Pharmaceutical Protections in U.S. Trade Deals “ What Do Americans Get in Return?. New England Journal of Medicine, 2019, 380, 1993-1995.	27.0	3
197	Experiences With and Challenges Afforded by Expedited Regulatory Pathways. Clinical Pharmacology and Therapeutics, 2019, 105, 795-797.	4.7	4
198	New Drug Formulations and Their Respective Generic Entry Dates. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 218-224.	0.9	4

#	ARTICLE	IF	CITATIONS
199	US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology. <i>JAMA Oncology</i> , 2019, 5, 607.	7.1	7
200	Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. <i>PLoS Medicine</i> , 2019, 16, e1002763.	8.4	55
201	Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes. <i>JAMA Network Open</i> , 2019, 2, e192224.	5.9	49
202	Variation in Prescription Drug Prices by Retail Pharmacy Type. <i>Annals of Internal Medicine</i> , 2019, 171, 605.	3.9	30
203	Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act. <i>Annals of Internal Medicine</i> , 2019, 171, 578.	3.9	0
204	Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis. <i>BMJ: British Medical Journal</i> , 2019, 366, l4257.	2.3	8
205	Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU. <i>BMJ Open</i> , 2019, 9, e028634.	1.9	24
206	The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation. <i>Journal of Law, Medicine and Ethics</i> , 2019, 47, 783-787.	0.9	0
207	Lifecycle Regulation of Artificial Intelligence- and Machine Learning-Based Software Devices in Medicine. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2285.	7.4	86
208	Changes in Drug Pricing After Drug Shortages in the United States. <i>Annals of Internal Medicine</i> , 2019, 170, 74.	3.9	16
209	Pain Management and Opioid Regulation: Continuing Public Health Challenges. <i>American Journal of Public Health</i> , 2019, 109, 31-34.	2.7	29
210	The <sc>US</sc> Biosimilar Market: Stunted Growth and Possible Reforms. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 92-100.	4.7	41
211	Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act. <i>JAMA Pediatrics</i> , 2019, 173, 68.	6.2	36
212	Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect. <i>JAMA Internal Medicine</i> , 2019, 179, 224.	5.1	26
213	A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications. <i>Journal of General Internal Medicine</i> , 2019, 34, 420-428.	2.6	8
214	An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?. <i>Nature Biotechnology</i> , 2019, 37, 21-22.	17.5	4
215	Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs. <i>JAMA Internal Medicine</i> , 2019, 179, 374.	5.1	18
216	The promise of ESCAT: a new system for evaluating cancer drug-target pairs. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 147-148.	27.6	9

#	ARTICLE	IF	CITATIONS
217	Internal Medicine Physicians' Financial Relationships with Industry: An Updated National Estimate. <i>Journal of General Internal Medicine</i> , 2019, 34, 195-197.	2.6	8
218	Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits?. <i>BMJ: British Medical Journal</i> , 2018, 360, k587.	2.3	24
219	The FDA Breakthrough-Drug Designation " Four Years of Experience. <i>New England Journal of Medicine</i> , 2018, 378, 1444-1453.	27.0	44
220	Application and impact of run-in studies. <i>Journal of General Internal Medicine</i> , 2018, 33, 759-763.	2.6	17
221	Prevalence of Publicly Available Expanded Access Policies. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1016-1021.	4.7	6
222	Tertiary patenting on drug-device combination products in the United States. <i>Nature Biotechnology</i> , 2018, 36, 142-145.	17.5	18
223	Research ethics for emerging trial designs: does equipoise need to adapt?. <i>BMJ: British Medical Journal</i> , 2018, 360, k226.	2.3	12
224	Legal Challenges to State Drug Pricing Laws. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 865.	7.4	0
225	Massachusetts' Proposed Medicaid Reforms " Cheaper Drugs and Better Coverage?. <i>New England Journal of Medicine</i> , 2018, 378, 109-111.	27.0	5
226	The Regulatory Accountability Act of 2017 " Implications for FDA Regulation and Public Health. <i>New England Journal of Medicine</i> , 2018, 378, 412-414.	27.0	2
227	Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. <i>BMJ: British Medical Journal</i> , 2018, 361, k1180.	2.3	27
228	Affordability and availability of off-patent drugs in the United States"the case for importing from abroad: observational study. <i>BMJ: British Medical Journal</i> , 2018, 360, k831.	2.3	16
229	Adaptive design clinical trials: a review of the literature and <i>ClinicalTrials.gov</i> . <i>BMJ Open</i> , 2018, 8, e018320.	1.9	106
230	Application and Impact of Run-In Studies for the Evaluation of Statin Efficacy and Safety. <i>Journal of General Internal Medicine</i> , 2018, 33, 792-794.	2.6	3
231	Use of Health Care Databases to Support Supplemental Indications of Approved Medications. <i>JAMA Internal Medicine</i> , 2018, 178, 55.	5.1	95
232	Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1093-1099.	4.7	13
233	Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007"2016. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky016.	2.9	12
234	Efficacy, Safety, and Regulatory Approval of Food and Drug Administration"Designated Breakthrough and Nonbreakthrough Cancer Medicines. <i>Journal of Clinical Oncology</i> , 2018, 36, 1805-1812.	1.6	72

#	ARTICLE	IF	CITATIONS
235	Can Outcomes-Based Pharmaceutical Contracts Reduce Drug Prices in the US? A Mixed Methods Assessment. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 952-963.	0.9	6
236	Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012. <i>JAMA Internal Medicine</i> , 2018, 178, 1458.	5.1	19
237	A Systematic Review Of The Food And Drug Administration's "Exception From Informed Consent" Pathway. <i>Health Affairs</i> , 2018, 37, 1605-1614.	5.2	24
238	The Tax Cuts and Jobs Act of 2017 and the Pharmaceutical Industry. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 806-808.	0.9	0
239	The FDA Amendments Act of 2007 "Assessing Its Effects a Decade Later. <i>New England Journal of Medicine</i> , 2018, 379, 1097-1099.	27.0	14
240	An Incomplete Prescription. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2373.	7.4	7
241	The Shortage of Normal Saline in the Wake of Hurricane Maria. <i>JAMA Internal Medicine</i> , 2018, 178, 885.	5.1	15
242	Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study. <i>Value in Health</i> , 2018, 21, 1286-1290.	0.3	39
243	Pharmaceutical Advertising in Medical Journals. <i>Chest</i> , 2018, 153, 9-11.	0.8	7
244	Reinforcing the social compromise of accelerated approval. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 596-597.	27.6	23
245	A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors. <i>JAMA Network Open</i> , 2018, 1, e180416.	5.9	45
246	Government Patent Use to Address the Rising Cost of Naloxone: 28 U.S.C. Â§ 1498 and Evzio. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 472-484.	0.9	2
247	Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period. <i>Health Affairs</i> , 2018, 37, 732-737.	5.2	40
248	Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines. <i>Health Affairs</i> , 2018, 37, 724-731.	5.2	27
249	Defining "True and Non-Misleading" for Pharmaceutical Promotion. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 552-554.	0.9	0
250	Changes in Outpatient Use of Antibiotics by Adults in the United States, 2006-2015. <i>Drug Safety</i> , 2018, 41, 1333-1342.	3.2	13
251	Delayed Generic Market Saturation After Patent Expiration "A Billion-Dollar Problem. <i>JAMA Internal Medicine</i> , 2018, 178, 721.	5.1	4
252	Expansion of the Priority Review Voucher Program Under the 21 <sup>st</sup> Century Cures Act: Implications for Innovation and Public Health. <i>American Journal of Law and Medicine</i> , 2018, 44, 329-341.	0.2	0

#	ARTICLE	IF	CITATIONS
253	U.S. Food and Drug Administration Precertification Pilot Program for Digital Health Software: Weighing the Benefits and Risks. <i>Annals of Internal Medicine</i> , 2018, 168, 730.	3.9	54
254	The next forum for unraveling FDA off-label marketing rules: State and federal legislatures. <i>PLoS Medicine</i> , 2018, 15, e1002564.	8.4	5
255	Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 650.	7.4	40
256	A Method for Approximating Future Entry of Generic Drugs. <i>Value in Health</i> , 2018, 21, 1382-1389.	0.3	21
257	Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis. <i>JMIR Public Health and Surveillance</i> , 2018, 4, e1.	2.6	21
258	Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. <i>Health Affairs</i> , 2017, 36, 362-370.	5.2	7
259	Prioritization of Generic Drug Reviewâ€”Reply. <i>JAMA Internal Medicine</i> , 2017, 177, 141.	5.1	3
260	Eliminating Coverage Discrimination Through the Essential Health Benefit's Anti-Discrimination Provisions. <i>American Journal of Public Health</i> , 2017, 107, 253-254.	2.7	1
261	Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study. <i>Drug Safety</i> , 2017, 40, 531-542.	3.2	21
262	Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence. <i>Drugs</i> , 2017, 77, 427-433.	10.9	7
263	Applying Academic Detailing and Process Change to Promote Choosing Wisely. <i>JAMA Internal Medicine</i> , 2017, 177, 282.	5.1	4
264	Strategies to improve the affordability of insulin in the USA. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 158-159.	11.4	33
265	FDA Approval of Eteplirsen for Muscular Dystrophyâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1481.	7.4	2
266	Ensuring Access to Injectable Generic Drugs â€” The Case of Intravesical BCG for Bladder Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1401-1403.	27.0	49
267	Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 694-701.	1.9	8
268	Medicaid Expenditures and Estimated Rebates for Epinephrine Autoinjectors, 2012 to 2016. <i>JAMA Internal Medicine</i> , 2017, 177, 734.	5.1	2
269	The Failure of Solanezumab â€” How the FDA Saved Taxpayers Billions. <i>New England Journal of Medicine</i> , 2017, 376, 1706-1708.	27.0	45
270	Three design aspects for high quality post-marketing cohort studies. <i>BMJ: British Medical Journal</i> , 2017, 357, j1851.	2.3	1



#	ARTICLE	IF	CITATIONS
271	Success, Failure, and Transparency in Biomarker-Based Drug Development. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	8
272	Coverage of Magnetic Resonance Imaging for Patients With Cardiac Devices. <i>JAMA Cardiology</i> , 2017, 2, 711.	6.1	8
273	Accelerated Approval and Expensive Drugs – A Challenging Combination. <i>New England Journal of Medicine</i> , 2017, 376, 2001-2004.	27.0	68
274	The Effects of the Sunshine Act: What Can and Should We Expect?. <i>American Journal of Bioethics</i> , 2017, 17, 22-24.	0.9	3
275	Periodic benefit–risk evaluation reports have substantial promise to guide patient care and should be made publicly available. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 597-599.	1.9	3
276	Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 712-721.	1.9	27
277	Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis. <i>Journal of Health Communication</i> , 2017, 22, 365-372.	2.4	18
278	FDA Approval of Desmopressin for Nocturia. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2059.	7.4	14
279	Review times and adverse events for cardiovascular devices. <i>Nature Biomedical Engineering</i> , 2017, 1, .	22.5	7
280	Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 290-296.	4.7	11
281	Reprioritizing Research Activity for the Post–Antibiotic Era: Ethical, Legal, and Social Considerations. <i>Hastings Center Report</i> , 2017, 47, 16-20.	1.0	8
282	The Fight Against Multidrug-Resistant Bacteria. <i>Annals of Internal Medicine</i> , 2017, 166, 79.	3.9	0
283	New “21st Century Cures” Legislation. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 581.	7.4	75
284	Strategies That Delay Market Entry of Generic Drugs. <i>JAMA Internal Medicine</i> , 2017, 177, 1665.	5.1	33
285	The Price of Crossing the Border for Medications. <i>New England Journal of Medicine</i> , 2017, 377, 1699-1700.	27.0	5
286	Low-Dose Desmopressin Nasal Spray and FDA Approval—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1071.	7.4	0
287	Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005–2014. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 156, 683-692.	1.9	2
288	Influence, integrity, and the FDA: An ethical framework. <i>Science</i> , 2017, 357, 876-877.	12.6	1

#	ARTICLE	IF	CITATIONS
289	Determinants of Market Exclusivity for Prescription Drugs in the United States. <i>JAMA Internal Medicine</i> , 2017, 177, 1658.	5.1	41
290	Association of the Priority Review Voucher With Neglected Tropical Disease Drug and Vaccine Development. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 388.	7.4	15
291	Both Urgency and Balance Needed in Addressing Opioid Epidemic. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 423.	7.4	54
292	The Price of Crossing the Border for Medications. <i>New England Journal of Medicine</i> , 2017, 377, 311-313.	27.0	11
293	Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 626.	7.4	148
294	The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2137.	7.4	62
295	Speed, Safety, and Industry Funding "From PDUFA I to PDUFA VI. <i>New England Journal of Medicine</i> , 2017, 377, 2278-2286.	27.0	31
296	Will inter partes review speed US generic drug entry?. <i>Nature Biotechnology</i> , 2017, 35, 1139-1141.	17.5	7
297	Public Participation in Drafting of the 21st Century Cures Act. <i>Journal of Law, Medicine and Ethics</i> , 2017, 45, 212-220.	0.9	0
298	Challenges in the Development of Novel Cardiovascular Therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 194-196.	4.7	6
299	Value-Based Pricing and State Reform of Prescription Drug Costs. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 609.	7.4	28
300	High Generic Drug Prices and Market Competition. <i>Annals of Internal Medicine</i> , 2017, 167, 145.	3.9	84
301	Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study. <i>European Journal of Cancer</i> , 2017, 70, 22-33.	2.8	28
302	Active Surveillance of Follow-on Biologics: A Prescription for Uptake. <i>Drug Safety</i> , 2017, 40, 105-108.	3.2	9
303	Prices of Generic Drugs Associated with Numbers of Manufacturers. <i>New England Journal of Medicine</i> , 2017, 377, 2597-2598.	27.0	71
304	Trends in Pricing and Generic Competition Within the Oral Antibiotic Drug Market in the United States. <i>Clinical Infectious Diseases</i> , 2017, 65, 1848-1852.	5.8	36
305	Evidence Required for Drugs Granted Accelerated Approval"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2493.	7.4	0
306	Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products. <i>Journal of Law, Medicine and Ethics</i> , 2017, 45, 7-23.	0.9	20

#	ARTICLE	IF	CITATIONS
307	Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study. <i>BMJ: British Medical Journal</i> , 2017, 358, j3837.	2.3	77
308	The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine. <i>PLoS ONE</i> , 2017, 12, e0175313.	2.5	3
309	Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 156, 285-288.	1.9	5
310	Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing. <i>Journal of Oncology Practice</i> , 2017, 13, 352-355.	2.5	30
311	The Real-World Ethics of Adaptive-Design Clinical Trials. <i>Hastings Center Report</i> , 2017, 47, 27-37.	1.0	18
312	Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. <i>PLoS Medicine</i> , 2017, 14, e1002190.	8.4	62
313	Outcomes-Based Pharmaceutical Contracts: An Answer to High U.S. Drug Spending?. <i>Issue Brief (Commonwealth Fund)</i> , 2017, 2017, 1-8.	0.9	11
314	Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad. <i>AMA Journal of Ethics</i> , 2016, 18, 727-735.	0.7	2
315	Drug Product Life-Cycle Management as Anticompetitive Behavior: The Case of Memantine. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 339-344.	0.9	4
316	Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis. <i>PLoS ONE</i> , 2016, 11, e0152195.	2.5	3
317	Navigating the Dermatological Drug Cost Curve. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2724.	7.4	1
318	Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 944-952.	1.9	5
319	Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending. <i>JAMA Internal Medicine</i> , 2016, 176, 1317.	5.1	32
320	Suitability of expanding the priority review voucher into rare disease drug development. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1001-1003.	0.8	1
321	Public referendum on drug prices in the US: will it bring relief?. <i>BMJ, The</i> , 2016, 355, i5657.	6.0	7
322	Factors Influencing Prescription Drug Costs in the United States—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2431.	7.4	1
323	Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010–2015. <i>Annals of Internal Medicine</i> , 2016, 165, 363.	3.9	81
324	Breakthrough Medical Devices and the 21st Century Cures Act. <i>Annals of Internal Medicine</i> , 2016, 164, 500.	3.9	11

#	ARTICLE	IF	CITATIONS
325	Efficacy of the Priority Review Voucher Program. JAMA - Journal of the American Medical Association, 2016, 315, 1660.	7.4	1
326	How Patent Troll Legislation Can Increase Timely Access to Generic Drugs. JAMA Internal Medicine, 2016, 176, 729.	5.1	11
327	Insulin patents and market exclusivities: unresolved issues – Authors' reply. Lancet Diabetes and Endocrinology, 2016, 4, 98-99.	11.4	6
328	Promoting Therapeutic Innovation: What Do We Do About Drug-Device Combinations?. JAMA - Journal of the American Medical Association, 2016, 315, 857.	7.4	0
329	Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation. JAMA - Journal of the American Medical Association, 2016, 315, 1516.	7.4	50
330	Prevalence and Predictors of Generic Drug Skepticism Among Physicians. JAMA Internal Medicine, 2016, 176, 845.	5.1	43
331	Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts. JAMA Internal Medicine, 2016, 176, 763.	5.1	171
332	"Government Patent Use": A Legal Approach To Reducing Drug Spending. Health Affairs, 2016, 35, 791-797.	5.2	23
333	Anti-VEGF therapy in ophthalmology: a qualitative analysis of transformative drug development. Drug Discovery Today, 2016, 21, 1019-1026.	6.4	4
334	Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. JACC Basic To Translational Science, 2016, 1, 301-308.	4.1	24
335	Switching generic antiepileptic drug manufacturer not linked to seizures. Neurology, 2016, 87, 1796-1801.	1.1	35
336	Prescription Trends – Brand-Name Drugs vs Generic – Reply. JAMA Internal Medicine, 2016, 176, 1574.	5.1	0
337	Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions – Reply. JAMA Internal Medicine, 2016, 176, 1577.	5.1	0
338	The US Food and Drug Administration 515 Program Initiative. JAMA Cardiology, 2016, 1, 117.	6.1	9
339	Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. JAMA Internal Medicine, 2016, 176, 1826.	5.1	279
340	Countering imprecision in precision medicine. Science, 2016, 353, 448-449.	12.6	33
341	The High Cost of Prescription Drugs in the United States. JAMA - Journal of the American Medical Association, 2016, 316, 858.	7.4	445
342	Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals. Bioorganic and Medicinal Chemistry, 2016, 24, 6446-6451.	3.0	11

#	ARTICLE	IF	CITATIONS
343	The FDA, Juno Therapeutics, and the ethical imperative of transparency. <i>BMJ, The</i> , 2016, 354, i4435.	6.0	6
344	Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections. <i>American Journal of Law and Medicine</i> , 2016, 42, 429-450.	0.2	4
345	Generic Drug Approvals Since the 1984 Hatch-Waxman Act. <i>JAMA Internal Medicine</i> , 2016, 176, 1391.	5.1	34
346	Translational research and the U.S. federal elections. <i>Science Translational Medicine</i> , 2016, 8, 361ed13.	12.4	1
347	Approving a Problematic Muscular Dystrophy Drug. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2357.	7.4	90
348	Regulating Off-Label Promotion – A Critical Test. <i>New England Journal of Medicine</i> , 2016, 375, 2313-2315.	27.0	11
349	Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study. <i>BMJ, The</i> , 2016, 353, i3323.	6.0	66
350	Use the Bayh-Dole Act to lower drug prices for government healthcare programs. <i>Nature Medicine</i> , 2016, 22, 576-576.	30.7	7
351	State Initiatives to Control Medication Costs – Can Transparency Legislation Help?. <i>New England Journal of Medicine</i> , 2016, 374, 2301-2304.	27.0	27
352	Regulating Homeopathic Products – A Century of Dilute Interest. <i>New England Journal of Medicine</i> , 2016, 374, 201-203.	27.0	11
353	Inaccurate Reporting of Insulin Reimbursement – Reply. <i>JAMA Internal Medicine</i> , 2016, 176, 408.	5.1	0
354	Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels. <i>Drug Safety</i> , 2016, 39, 709-714.	3.2	7
355	Vaccine Pipeline Has Grown During The Past Two Decades With More Early-Stage Trials From Small And Medium-Size Companies. <i>Health Affairs</i> , 2016, 35, 219-226.	5.2	9
356	Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey. <i>Journal of General Internal Medicine</i> , 2016, 31, 609-614.	2.6	53
357	The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?. <i>PLoS Medicine</i> , 2016, 13, e1001955.	8.4	7
358	An Uninformative Truth: The Logic of Amarin's Off-Label Promotion. <i>PLoS Medicine</i> , 2016, 13, e1001978.	8.4	6
359	Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval. <i>PLoS ONE</i> , 2016, 11, e0163339.	2.5	8
360	Regulatory Solutions to the Problem of High Generic Drug Costs. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv179.	0.9	4

#	ARTICLE	IF	CITATIONS
361	Prescription Drug Insurance Coverage and Patient Health Outcomes: A Systematic Review. American Journal of Public Health, 2015, 105, e17-e30.	2.7	64
362	Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ, The, 2015, 351, h4633.	6.0	143
363	Are Risk Evaluation and Mitigation Strategies Associated With Less Off-Label Use of Medications? The Case of Immune Thrombocytopenia. Clinical Pharmacology and Therapeutics, 2015, 97, 186-193.	4.7	11
364	Uptake of the First Biosimilar Infliximab since its Approval in South Korea. Arthritis and Rheumatology, 2015, 68, n/a-n/a.	5.6	12
365	Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study. Milbank Quarterly, 2015, 93, 761-787.	4.4	14
366	Medical Schools' Industry Interaction Policies Not Associated With Trainees' Self-Reported Behavior as Residents: Results of a National Survey. Journal of Graduate Medical Education, 2015, 7, 595-602.	1.3	12
367	Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review. BMJ, The, 2015, 351, h4679.	6.0	31
368	Accelerating innovation in rapid diagnostics and targeted antibacterials. Nature Biotechnology, 2015, 33, 589-590.	17.5	8
369	The 21st Century Cures Act "Will It Take Us Back in Time?". New England Journal of Medicine, 2015, 372, 2473-2475.	27.0	116
370	The 21st century cures act: Opportunities and challenges. Clinical Pharmacology and Therapeutics, 2015, 98, 575-577.	4.7	6
371	A cross-national comparison of 17 countries' insulin glargine drug labels. Pharmacoepidemiology and Drug Safety, 2015, 24, 159-165.	1.9	5
372	Physicians and Insider Trading. JAMA Internal Medicine, 2015, 175, 1955.	5.1	4
373	FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes. Clinical Pharmacology and Therapeutics, 2015, 97, 29-36.	4.7	36
374	Availability and utilization of cardiovascular fixed-dose combination drugs in the United States. American Heart Journal, 2015, 169, 379-386.e1.	2.7	22
375	Development and Use of New Therapeutics for Rare Diseases: Views from Patients, Caregivers, and Advocates. Patient, 2015, 8, 75-84.	2.7	26
376	Medical Device Postapproval Safety Monitoring. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 124-131.	2.2	31
377	Propofol as a transformative drug in anesthesia: insights from key early investigators. Drug Discovery Today, 2015, 20, 1012-1017.	6.4	20
378	High-Cost Generic Drugs "Implications for Patients and Policymakers. New England Journal of Medicine, 2015, 372, 685-686.	27.0	10

#	ARTICLE	IF	CITATIONS
379	The Safety of Prescription Drugs. JAMA - Journal of the American Medical Association, 2015, 314, 233.	7.4	6
380	Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States. PLoS Medicine, 2015, 12, e1001802.	8.4	13
381	Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness. Drug Safety, 2015, 38, 849-853.	3.2	7
382	Mandatory Disclaimers On Dietary Supplements Do Not Reliably Communicate The Intended Issues. Health Affairs, 2015, 34, 438-446.	5.2	29
383	Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. Journal of General Internal Medicine, 2015, 30, 1633-1638.	2.6	18
384	Precision medicine and the FDA's draft guidance on laboratory-developed tests. Nature Biotechnology, 2015, 33, 449-451.	17.5	9
385	Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications. Drug Safety, 2015, 38, 565-575.	3.2	31
386	The Watchman Saga " Closure at Last?. New England Journal of Medicine, 2015, 372, 994-995.	27.0	7
387	The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs. Health Affairs, 2015, 34, 286-293.	5.2	73
388	Variations in Time of Market Exclusivity Among Top-Selling Prescription Drugs in the United States. JAMA Internal Medicine, 2015, 175, 635.	5.1	39
389	Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes. Drugs, 2015, 75, 633-650.	10.9	8
390	Paying for innovation: Reimbursement incentives for antibiotics. Science Translational Medicine, 2015, 7, 276fs9.	12.4	11
391	Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy and Behavior, 2015, 52, 14-18.	1.7	38
392	Experience With the Priority Review Voucher Program for Drug Development. JAMA - Journal of the American Medical Association, 2015, 314, 1687.	7.4	30
393	FDA Policy and Cardiovascular Medicine. Circulation, 2015, 132, 1136-1145.	1.6	7
394	The 21st Century Cures Act. New England Journal of Medicine, 2015, 373, 1677-1680.	27.0	13
395	Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs. New England Journal of Medicine, 2015, 372, 279-286.	27.0	125
396	Progress and Hurdles for Follow-on Biologics. New England Journal of Medicine, 2015, 372, 2380-2382.	27.0	43

#	ARTICLE	IF	CITATIONS
397	The Trans-Pacific Partnership Agreement and Implications for Access to Essential Medicines. JAMA - Journal of the American Medical Association, 2015, 314, 1563.	7.4	8
398	Expanded Access to Investigational Drugs. New England Journal of Medicine, 2015, 372, 1473-1474.	27.0	3
399	Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014. JAMA Internal Medicine, 2015, 175, 1681.	5.1	41
400	Forbidden and Permitted Statements about Medications "Loosening the Rules. New England Journal of Medicine, 2015, 373, 967-973.	27.0	12
401	Cost-effectiveness of Statin Therapy for ASCVD. JAMA - Journal of the American Medical Association, 2015, 314, 2191.	7.4	0
402	Evolution of insulin patents and market exclusivities in the USA. Lancet Diabetes and Endocrinology, the, 2015, 3, 835-837.	11.4	23
403	Two decades of new drug development for central nervous system disorders. Nature Reviews Drug Discovery, 2015, 14, 815-816.	46.4	111
404	Prospects for Regulation of Off-Label Drug Promotion in an Era of Expanding Commercial Speech Protection. , 2015, , 184-203.		0
405	A New Wave of Vaccines for Non-Communicable Diseases: What Are the Regulatory Challenges?. Food and Drug Law Journal, 2015, 70, 243-58, i.	0.4	5
406	Evidence, Errors, and Ethics. Perspectives in Biology and Medicine, 2014, 57, 299-307.	0.5	5
407	Drug Development and FDA Approval, 1938"2013. New England Journal of Medicine, 2014, 370, e39.	27.0	39
408	Existing FDA Pathways Have Potential To Ensure Early Access To, And Appropriate Use Of, Specialty Drugs. Health Affairs, 2014, 33, 1770-1778.	5.2	13
409	Association of Medical Students' Reports of Interactions with the Pharmaceutical and Medical Device Industries and Medical School Policies and Characteristics: A Cross-Sectional Study. PLoS Medicine, 2014, 11, e1001743.	8.4	11
410	Restrictions On Pharmaceutical Detailing Reduced Off-Label Prescribing Of Antidepressants And Antipsychotics In Children. Health Affairs, 2014, 33, 1014-1023.	5.2	40
411	New FDA Breakthrough-Drug Category " Implications for Patients. New England Journal of Medicine, 2014, 370, 1252-1258.	27.0	102
412	Ensuring Patient Privacy in Data Sharing for Postapproval Research. New England Journal of Medicine, 2014, 371, 1644-1649.	27.0	19
413	Burden of Changes in Pill Appearance for Patients Receiving Generic Cardiovascular Medications After Myocardial Infarction. Annals of Internal Medicine, 2014, 161, 96.	3.9	74
414	Health Policy Basics: The Physician Payment Sunshine Act and the Open Payments Program. Annals of Internal Medicine, 2014, 161, 519.	3.9	83



#	ARTICLE	IF	CITATIONS
415	Regulating incremental innovation in medical devices. <i>BMJ, The</i> , 2014, 349, g5303-g5303.	6.0	9
416	Using a Drug-Safety Tool to Prevent Competition. <i>New England Journal of Medicine</i> , 2014, 370, 1476-1478.	27.0	21
417	New FDA Breakthrough-Drug Category â€” Implications for Patients. <i>New England Journal of Medicine</i> , 2014, 371, 87-90.	27.0	9
418	The Pharmaceutical Marketâ€™s Adverse Effects. <i>Health Affairs</i> , 2014, 33, 179-180.	5.2	0
419	Innovative research methods for studying treatments for rare diseases: methodological review. <i>BMJ, The</i> , 2014, 349, g6802-g6802.	6.0	144
420	Strategies for Postmarketing Surveillance of Drugs for Rare Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 265-268.	4.7	36
421	Association of Marketing Interactions With Medical Traineesâ€™ Knowledge About Evidence-Based Prescribing. <i>JAMA Internal Medicine</i> , 2014, 174, 1283.	5.1	43
422	Quantifying The Food And Drug Administrationâ€™s Rulemaking Delays Highlights The Need For Transparency. <i>Health Affairs</i> , 2014, 33, 309-315.	5.2	12
423	Life Cycle of Medical Product Rules Issued by the US Food and Drug Administration. <i>Journal of Health Politics, Policy and Law</i> , 2014, 39, 751-780.	1.9	8
424	Chemotherapy Parity Laws. <i>JAMA Internal Medicine</i> , 2014, 174, 1721.	5.1	11
425	The Food and Drug Administrationâ€™s Role in Promoting Consistent Labels for Generic Drugs. <i>JAMA Internal Medicine</i> , 2014, 174, 1213.	5.1	1
426	Electronic Medication Packaging Devices and Medication Adherence. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1237.	7.4	159
427	What Is the Publicâ€™s Right to Access Medical Discoveries Based on Federally Funded Research?. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 907.	7.4	8
428	Underrepresentation of Older Adults in Cancer Trials. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 965.	7.4	5
429	Medical Innovation Then and Now: Perspectives of Innovators Responsible for Transformative Drugs. <i>Journal of Law, Medicine and Ethics</i> , 2014, 42, 564-575.	0.9	9
430	Target small firms for antibiotic innovation. <i>Science</i> , 2014, 344, 967-969.	12.6	15
431	FDA Approval of Cardiac Implantable Electronic Devices via Original and Supplement Premarket Approval Pathways, 1979-2012. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 385.	7.4	58
432	The Evolving Role of Biomarker Patents in Personalized Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 127-129.	4.7	9

#	ARTICLE	IF	CITATIONS
433	High-Cost Generic Drugs â€™ Implications for Patients and Policymakers. <i>New England Journal of Medicine</i> , 2014, 371, 1859-1862.	27.0	89
434	FDA Regulation of Mobile Health Technologies. <i>New England Journal of Medicine</i> , 2014, 371, 372-379.	27.0	222
435	Introduction to a Supplement on Innovative Approaches to Studying Health Outcomes in Rare Diseases. <i>Journal of General Internal Medicine</i> , 2014, 29, 709-711.	2.6	2
436	Postmarketing Trials and Pediatric Device Approvals. <i>Pediatrics</i> , 2014, 133, e1197-e1202.	2.1	39
437	Approval of High-Risk Medical Devices in the US: Implications for Clinical Cardiology. <i>Current Cardiology Reports</i> , 2014, 16, 489.	2.9	26
438	Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes. <i>Annals of Internal Medicine</i> , 2014, 161, 400.	3.9	137
439	Burden of Changes in Generic Pill Appearance. <i>Annals of Internal Medicine</i> , 2014, 161, 840.	3.9	2
440	Assessment of US pathway for approving medical devices for rare conditions. <i>BMJ, The</i> , 2014, 348, g217-g217.	6.0	13
441	Cliniciansâ€™™ Contributions to the Development of Coronary Artery Stents: A Qualitative Study of Transformative Device Innovation. <i>PLoS ONE</i> , 2014, 9, e88664.	2.5	12
442	Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011. <i>American Journal of Managed Care</i> , 2014, 20, e90-7.	1.1	23
443	Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey. <i>Journal of General Internal Medicine</i> , 2013, 28, 1064-1071.	2.6	59
444	Physician Traineesâ€™™ Interactions with the Pharmaceutical Industry. <i>Journal of General Internal Medicine</i> , 2013, 28, 1267-1267.	2.6	3
445	Defining â€™œInnovativenessâ€™•in Drug Development: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 336-348.	4.7	40
446	Gene Patenting â€™™ The Supreme Court Finally Speaks. <i>New England Journal of Medicine</i> , 2013, 369, 869-875.	27.0	58
447	Clinical and Regulatory Features of Drugs Not Initially Approved by the FDA. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 670-677.	4.7	14
448	Approval and Withdrawal of New Antibiotics and other Antiinfectives in the U.S., 1980â€™•2009. <i>Journal of Law, Medicine and Ethics</i> , 2013, 41, 688-696.	0.9	38
449	The most transformative drugs of the past 25 years: a survey of physicians. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 425-431.	46.4	39
450	Distributions of Industry Payments to Massachusetts Physicians. <i>New England Journal of Medicine</i> , 2013, 368, 2049-2052.	27.0	50

#	ARTICLE	IF	CITATIONS
451	Variations in Pill Appearance of Antiepileptic Drugs and the Risk of Nonadherence. <i>JAMA Internal Medicine</i> , 2013, 173, 202.	5.1	102
452	The Medical Device Excise Tax "Over before It Begins?. <i>New England Journal of Medicine</i> , 2013, 369, 982-985.	27.0	0
453	Prescription-Drug Coupons "No Such Thing as a Free Lunch. <i>New England Journal of Medicine</i> , 2013, 369, 1188-1189.	27.0	57
454	The Medical Device Excise Tax "Over before It Begins?. <i>New England Journal of Medicine</i> , 2013, 368, 1767-1769.	27.0	4
455	Postmarket Surveillance of Medical Devices: A Comparison of Strategies in the US, EU, Japan, and China. <i>PLoS Medicine</i> , 2013, 10, e1001519.	8.4	32
456	Same Song, Different Audience: Pharmaceutical Promotion Targeting Non-Physician Health Care Providers. <i>PLoS Medicine</i> , 2013, 10, e1001560.	8.4	3
457	Rising Health Care Costs and Life-Cycle Management in the Pharmaceutical Market. <i>PLoS Medicine</i> , 2013, 10, e1001461.	8.4	9
458	Who Is Now Responsible for Discovering and Warning About Adverse Effects of Generic Drugs?. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1023.	7.4	6
459	Patterns and Predictors of Generic Narrow Therapeutic Index Drug Use Among Older Adults. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 1586-1591.	2.6	19
460	Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs. <i>BMJ Quality and Safety</i> , 2013, 22, 727-734.	3.7	29
461	The Ethics of Intellectual Property Rights in an Era of Globalization. <i>Journal of Law, Medicine and Ethics</i> , 2013, 41, 841-851.	0.9	9
462	FDA Regulation of Off-label Drug Promotion Under Attack. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 445.	7.4	11
463	New and unproved medical devices. <i>BMJ, The</i> , 2013, 347, f7413-f7413.	6.0	7
464	Balancing Access and Innovation. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 263.	7.4	2
465	Drug company gifts to medical students: the hidden curriculum. <i>BMJ, The</i> , 2013, 346, f1113-f1113.	6.0	2
466	The Role of Direct-to-Consumer Pharmaceutical Advertising in Patient Consumerism. <i>AMA Journal of Ethics</i> , 2013, 15, 960-965.	0.7	13
467	Off-Label Drug Use: The Authors Reply. <i>Health Affairs</i> , 2012, 31, 460-460.	5.2	0
468	How Does Medical Device Regulation Perform in the United States and the European Union? A Systematic Review. <i>PLoS Medicine</i> , 2012, 9, e1001276.	8.4	108

#	ARTICLE	IF	CITATIONS
469	Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures. <i>PLoS Medicine</i> , 2012, 9, e1001280.	8.4	68
470	Changes in Direct-to-Consumer Pharmaceutical Advertising Following Shifts From Prescription-Only to Over-the-Counter Status. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 973.	7.4	14
471	The Food And Drug Administration Has The Legal Basis To Restrict Promotion Of Flawed Comparative Effectiveness Research. <i>Health Affairs</i> , 2012, 31, 2200-2205.	5.2	11
472	Paying for Tissue: Net Benefitsâ€™Response. <i>Science</i> , 2012, 337, 1293-1293.	12.6	0
473	User Fees and Beyond â€™ The FDA Safety and Innovation Act of 2012. <i>New England Journal of Medicine</i> , 2012, 367, 1277-1279.	27.0	26
474	Risk, Responsibility, and Generic Drugs. <i>New England Journal of Medicine</i> , 2012, 367, 1679-1681.	27.0	6
475	A Randomized Study of How Physicians Interpret Research Funding Disclosures. <i>New England Journal of Medicine</i> , 2012, 367, 1119-1127.	27.0	165
476	Origins of Medical Innovation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 743-749.	2.2	20
477	Drug Labels: A Flawed Source of Data for Studying Orphan Drug Approvals. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 694-694.	4.7	1
478	Insights from a National Conference: â€™Conflicts of Interest in the Practice of Medicineâ€™. <i>Journal of Law, Medicine and Ethics</i> , 2012, 40, 436-440.	0.9	5
479	Effect of Financial Relationships on the Behaviors of Health Care Professionals: A Review of the Evidence. <i>Journal of Law, Medicine and Ethics</i> , 2012, 40, 452-466.	0.9	64
480	Secondary Patenting Of Branded Pharmaceuticals: A Case Study Of How Patents On Two HIV Drugs Could Be Extended For Decades. <i>Health Affairs</i> , 2012, 31, 2286-2294.	5.2	52
481	Regulation of Medical Devices in the United States and European Union. <i>New England Journal of Medicine</i> , 2012, 366, 848-855.	27.0	218
482	Paying Patients for Their Tissue: The Legacy of Henrietta Lacks. <i>Science</i> , 2012, 337, 37-38.	12.6	41
483	Ethical Considerations in Orphan Drug Approval and Use. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 153-155.	4.7	12
484	The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs. <i>PLoS ONE</i> , 2012, 7, e31894.	2.5	45
485	Biomarkers Unbound â€™ The Supreme Court's Ruling on Diagnostic-Test Patents. <i>New England Journal of Medicine</i> , 2012, 366, 2338-2340.	27.0	12
486	Conflict of interest in oncology publications. <i>Cancer</i> , 2012, 118, 188-195.	4.1	27

#	ARTICLE	IF	CITATIONS
487	Ethical Issues in New Drug Prescribing. <i>Journal of Bioethical Inquiry</i> , 2012, 9, 77-83.	1.5	4
488	Why Do the Same Drugs Look Different? Pills, Trade Dress, and Public Health. <i>New England Journal of Medicine</i> , 2011, 365, 83-89.	27.0	71
489	Safety, Supply, and Suits – Litigation and the Vaccine Industry. <i>New England Journal of Medicine</i> , 2011, 364, 1485-1487.	27.0	5
490	The Consequences of Requesting “Dispense as Written”. <i>American Journal of Medicine</i> , 2011, 124, 309-317.	1.5	39
491	Generic Immunosuppressants in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 285-290.	2.0	12
492	A Hemorrhage of Off-Label Use. <i>Annals of Internal Medicine</i> , 2011, 154, 566.	3.9	47
493	Off-Label Drug Use and Promotion: Balancing Public Health Goals and Commercial Speech. <i>American Journal of Law and Medicine</i> , 2011, 37, 225-257.	0.2	16
494	An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences. <i>Milbank Quarterly</i> , 2011, 89, 450-502.	4.4	46
495	Where Cost, Medical Necessity, and Morality Meet: Should US Government Insurance Programs Pay for Erectile Dysfunction Drugs?. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 17-19.	4.7	18
496	Ethical and Legal Views Regarding Deactivation of Cardiac Implantable Electrical Devices in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2011, 107, 1071-1075.e5.	1.6	34
497	Clinical Decision Support Systems Could Be Modified To Reduce “Alert Fatigue” While Still Minimizing The Risk Of Litigation. <i>Health Affairs</i> , 2011, 30, 2310-2317.	5.2	224
498	Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2320.	7.4	190
499	“Pay for Delay” Settlements of Disputes over Pharmaceutical Patents. <i>New England Journal of Medicine</i> , 2011, 365, 1439-1445.	27.0	23
500	Residents: Workers or Students in the Eyes of the Law?. <i>New England Journal of Medicine</i> , 2011, 364, 697-699.	27.0	10
501	Reputation and Precedent in the Bevacizumab Decision. <i>New England Journal of Medicine</i> , 2011, 365, e3.	27.0	63
502	Who Owns Federally Funded Research? The Supreme Court and the Bayh-Dole Act. <i>New England Journal of Medicine</i> , 2011, 365, 1167-1169.	27.0	5
503	Covert pharmaceutical promotion in free medical journals. <i>Cmaj</i> , 2011, 183, 534-535.	2.0	4
504	The backlash against bioequivalence and the interchangeability of brand-name and generic drugs. <i>Cmaj</i> , 2011, 183, 1350-1351.	2.0	12

#	ARTICLE	IF	CITATIONS
505	Clinical Trials of Orphan Drugs for Cancer—Reply. JAMA - Journal of the American Medical Association, 2011, 306, 1545.	7.4	1
506	Conflict of Interest Disclosure in Early Education of Medical Students. JAMA - Journal of the American Medical Association, 2011, 306, 991-2.	7.4	14
507	False Claims Act Prosecution Did Not Deter Off-Label Drug Use In The Case Of Neurontin. Health Affairs, 2011, 30, 2318-2327.	5.2	34
508	Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology, 2011, 40, 1732-1734.	1.9	81
509	The NIH translational research center might trade public risk for private reward. Nature Medicine, 2011, 17, 1176-1176.	30.7	7
510	Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints. PLoS Medicine, 2011, 8, e1000431.	8.4	88
511	Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: A Systematic Review. PLoS Medicine, 2011, 8, e1001037.	8.4	97
512	A Hemorrhage of Off-Label Use. Annals of Internal Medicine, 2011, 155, 339.	3.9	0
513	Improving antibiotic markets for long-term sustainability. Yale Journal of Health Policy, Law, and Ethics, 2011, 11, 101-67.	1.5	16
514	Reviews in Medical Ethics. Journal of Law, Medicine and Ethics, 2010, 38, 427-435.	0.9	0
515	Using malpractice claims to identify risk factors for neurological impairment among infants following non-reassuring fetal heart rate patterns during labour. Journal of Evaluation in Clinical Practice, 2010, 16, 476-483.	1.8	4
516	Permitting Product Liability Litigation for FDA-Approved Drugs and Devices Promotes Patient Safety. Clinical Pharmacology and Therapeutics, 2010, 87, 645-647.	4.7	11
517	State Generic Substitution Laws Can Lower Drug Outlays Under Medicaid. Health Affairs, 2010, 29, 1383-1390.	5.2	78
518	Questions about the 10 – 20 Initiative. Clinical Infectious Diseases, 2010, 51, 751-752.	5.8	6
519	Designing Comparative Effectiveness Research On Prescription Drugs: Lessons From The Clinical Trial Literature. Health Affairs, 2010, 29, 1842-1848.	5.2	27
520	Adalimumab Pricing and Market Exclusivity for Biologics. New England Journal of Medicine, 2010, 363, 2374-2374.	27.0	0
521	Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation. New England Journal of Medicine, 2010, 363, 1855-1862.	27.0	54
522	Incentives for Drug Development – The Curious Case of Colchicine. New England Journal of Medicine, 2010, 362, 2045-2047.	27.0	64

#	ARTICLE	IF	CITATIONS
523	Whistle-Blowers' Experiences in Fraud Litigation against Pharmaceutical Companies. <i>New England Journal of Medicine</i> , 2010, 362, 1832-1839.	27.0	46
524	Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: A quantitative assessment. <i>Heart Rhythm</i> , 2010, 7, 1537-1542.	0.7	67
525	Pharmaceutical Marketing and the New Social Media. <i>New England Journal of Medicine</i> , 2010, 363, 2087-2089.	27.0	67
526	Gene Patenting "Is the Pendulum Swinging Back?". <i>New England Journal of Medicine</i> , 2010, 362, 1855-1858.	27.0	21
527	Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs. <i>Drugs</i> , 2010, 70, 605-621.	10.9	164
528	Fighting Antibiotic Resistance: Marrying New Financial Incentives To Meeting Public Health Goals. <i>Health Affairs</i> , 2010, 29, 1689-1696.	5.2	55
529	Physician Ethical and Legal Views Regarding Deactivation of Cardiac Implantable Electrical Devices. <i>Journal of Cardiac Failure</i> , 2010, 16, S106.	1.7	0
530	Managing Financial and Nonfinancial Conflicts of Interest in Healthcare Delivery. <i>American Journal of Therapeutics</i> , 2010, 17, 440-443.	0.9	6
531	Equivalence of Generic and Brand-Name Drugs for Cardiovascular Disease"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1654.	7.4	0
532	How Medicare Could Get Better Prices On Prescription Drugs. <i>Health Affairs</i> , 2009, 28, w832-w841.	5.2	19
533	The Supreme Court, Preemption, and Malpractice Liability. <i>New England Journal of Medicine</i> , 2009, 360, 559-561.	27.0	8
534	The Supreme Court, Process Patents, and Medical Innovation. <i>New England Journal of Medicine</i> , 2009, 361, 2303-2306.	27.0	2
535	Expert Review Of Drug Patent Applications: Improving Health In The Developing World. <i>Health Affairs</i> , 2009, 28, w948-w956.	5.2	2
536	Priority Review Vouchers: An Inefficient and Dangerous Way to Promote Neglected-Disease Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 573-575.	4.7	10
537	Using Patent Data to Assess the Value of Pharmaceutical Innovation. <i>Journal of Law, Medicine and Ethics</i> , 2009, 37, 176-183.	0.9	8
538	Balancing Innovation, Access, and Profits "Market Exclusivity for Biologics. <i>New England Journal of Medicine</i> , 2009, 361, 1917-1919.	27.0	54
539	Professional Oversight of Physician Expert Witnesses. <i>Annals of Surgery</i> , 2009, 249, 168-172.	4.2	5
540	Drug Development for Neglected Diseases "The Trouble with FDA Review Vouchers. <i>New England Journal of Medicine</i> , 2008, 359, 1981-1983.	27.0	36

#	ARTICLE	IF	CITATIONS
541	Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2008, 300, 2514.	7.4	360
542	Rethinking global access to vaccines. BMJ: British Medical Journal, 2008, 336, 750-753.	2.3	48
543	Market-Based Licensing For HPV Vaccines In Developing Countries. Health Affairs, 2008, 27, 130-139.	5.2	23
544	Regulating Physician Expert Witness Testimonyâ€”Reply. JAMA - Journal of the American Medical Association, 2008, 299, 1667.	7.4	0
545	Scientific and Legal Viability of Follow-on Protein Drugs. New England Journal of Medicine, 2008, 358, 843-849.	27.0	48
546	Pharmaceutical Promotion to Physicians and First Amendment Rights. New England Journal of Medicine, 2008, 358, 1727-1732.	27.0	32
547	The International Pharmaceutical Market as a Source of Low-Cost Prescription Drugs for U.S. Patients. Annals of Internal Medicine, 2008, 148, 614.	3.9	14
548	Think Globally, Prescribe Locally: How Rational Pharmaceutical Policy in the U.S. Can Improve Global Access to Essential Medicines. American Journal of Law and Medicine, 2008, 34, 125-139.	0.2	6
549	Whistleblower-Initiated Enforcement Actions against Health Care Fraud and Abuse in the United States, 1996 to 2005. Annals of Internal Medicine, 2008, 149, 342.	3.9	28
550	The Role of Litigation in Defining Drug Risks. JAMA - Journal of the American Medical Association, 2007, 297, 308.	7.4	53
551	Confidentiality Laws And Secrecy In Medical Research: Improving Public Access To Data On Drug Safety. Health Affairs, 2007, 26, 483-491.	5.2	83
552	Role of Professional Organizations in Regulating Physician Expert Witness Testimony. JAMA - Journal of the American Medical Association, 2007, 298, 2907.	7.4	24
553	Brand-Name Versus Generic: The Authors Respond. Health Affairs, 2007, 26, 1199-1199.	5.2	0
554	Intellectual property policy in the pharmaceutical sciences: The effect of inappropriate patents and market exclusivity extensions on the health care system. AAPS Journal, 2007, 9, E306-E311.	4.4	25
555	Biomedical Patents and the Public's Health. JAMA - Journal of the American Medical Association, 2006, 295, 434.	7.4	22
556	Characteristics of Physicians Who Frequently Act as Expert Witnesses in Neurologic Birth Injury Litigation. Obstetrics and Gynecology, 2006, 108, 273-279.	2.4	31
557	Characteristics of Physicians Who Frequently Act as Expert Witnesses in Neurologic Birth Injury Litigation. Obstetrics and Gynecology, 2006, 108, 1553.	2.4	1
558	Medical-Process Patents â€” Monopolizing the Delivery of Health Care. New England Journal of Medicine, 2006, 355, 2036-2041.	27.0	16



#	ARTICLE	IF	CITATIONS
559	Creating a Medical, Ethical, and Legal Framework for Complex Living Kidney Donors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1148-1153.	4.5	66
560	The Rise And Fall Of Natrecor For Congestive Heart Failure: Implications For Drug Policy. <i>Health Affairs</i> , 2006, 25, 1095-1102.	5.2	18
561	Will Physician-Level Measures of Clinical Performance Be Used in Medical Malpractice Litigation?. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1831.	7.4	20
562	Extensions Of Intellectual Property Rights And Delayed Adoption Of Generic Drugs: Effects On Medicaid Spending. <i>Health Affairs</i> , 2006, 25, 1637-1647.	5.2	43
563	Clinical Performance Measures and Medical Malpractice—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1585.	7.4	0
564	Contrast-induced nephropathy: how it develops, how to prevent it.. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 75-80.	1.3	68
565	Overbilling vs. Downcoding — The Battle between Physicians and Insurers. <i>New England Journal of Medicine</i> , 2005, 352, 855-857.	27.0	17
566	University-Based Science and Biotechnology Products. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 850.	7.4	29
567	PRIVACY VERSUS THE PUBLIC'S RIGHT TO KNOW - PRESIDENTIAL HEALTH AND THE WHITE HOUSE PHYSICIAN. <i>Journal of Legal Medicine</i> , 2002, 23, 523-545.	0.5	2
568	What's the Appeal? Trying to Control Managed Care Medical Necessity Decisionmaking through a System of External Appeals. <i>University of Pennsylvania Law Review</i> , 2001, 149, 873.	0.3	9